Glaukos (GKOS) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 net sales reached $211.0 million, up 58% year over year and above the roughly $168 million consensus estimate.
• Glaukos swung to GAAP net income of $2.0 million, or $0.03 per diluted share, compared with a loss of $16.2 million a year earlier.
• Adjusted (non-GAAP) diluted earnings per share came in at $0.47, sharply above the consensus expectation of a $0.10 loss.
• Management raised full-year 2026 revenue guidance to $775 million–$785 million and introduced preliminary 2027 sales guidance of about $1 billion.
• Growth was driven primarily by the iDose TR glaucoma implant and the newly launched Epioxa corneal therapy.
• For more on GKOS, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover new trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders, and retinal diseases, entered this report with elevated expectations. The stock had already recovered sharply from its 52-week low and traded near record levels, meaning investors were looking for proof that its two growth engines could scale. The iDose TR implant has been lifting the U.S. glaucoma franchise, while Epioxa, launched commercially in March 2026, has been ramping through an expanding network of treatment sites. With the company still unprofitable on a GAAP (Generally Accepted Accounting Principles) basis in recent quarters, this report served as a key test of whether rapid revenue growth could finally translate into operating leverage and a clear path toward sustainable profitability.

Reported Results

Glaukos reported third quarter 2026 net sales of $211.0 million, a 58% increase from $133.5 million in the prior-year period and ahead of the consensus estimate of roughly $168 million. U.S. glaucoma revenue rose 47% to a record $118.6 million, while corneal health revenue jumped 154% to $59 million, reflecting the accelerating Epioxa launch. International glaucoma revenue increased 13.3% to about $33.4 million.

The company swung to GAAP net income of $2.0 million, or $0.03 per diluted share, from a loss of $16.2 million, or $0.28 per share, a year ago. On an adjusted (non-GAAP) basis, which excludes acquisition-related and other items, net income was $28.5 million, or $0.47 per diluted share — far exceeding the consensus forecast of a $0.10 loss and marking the company's first adjusted profit in eight quarters. GAAP gross margin expanded to roughly 85% from about 78% a year earlier.

Management raised its full-year 2026 revenue guidance to $775 million–$785 million, up from the prior range of $680 million–$700 million, and offered preliminary 2027 net sales guidance of approximately $1 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking momentum in high-growth medical technology names like Glaukos, it offers a structured way to surface comparable opportunities across sectors.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was cautiously optimistic but sensitive to valuation. Analysts widely rated the stock a strong buy, with the consensus price target implying modest upside from near-record levels, yet the shares had sold off more than 13% in early October following positive three-year Epioxa trial data amid valuation concerns. The third quarter's revenue beat, the swing to adjusted profitability, and the sharply raised guidance addressed the central question investors were asking: whether the growth story could convert into improving margins. The introduction of a $1 billion preliminary 2027 sales target provided a concrete forward milestone that had not previously been disclosed, reinforcing confidence in the durability of the iDose TR and Epioxa franchises.

Forward Outlook and Key Factors to Monitor

The raised full-year 2026 guidance and the new preliminary 2027 target of roughly $1 billion in net sales suggest management expects the current momentum to continue. Still, several factors will determine whether that trajectory holds. Reimbursement remains a key watchpoint: proposed Local Coverage Determinations affecting iDose TR, as well as potential physician fee reductions for cataract and MIGS (micro-invasive glaucoma surgery) procedures, could influence procedure volumes and pricing.

For Epioxa, the focus is on operational execution. The July 1, 2026 activation of its product-specific J-code, J2789, was an important step in streamlining reimbursement, and investors will monitor how quickly coverage pathways convert into treatment volume as the company expands toward sites covering more than 95% of the U.S. population.

Finally, cost discipline matters. Even as gross margins expand, selling, general, and administrative expenses have been rising with commercial buildout, and research and development spending remains elevated. Whether Glaukos can sustain its adjusted profitability while funding further launches will be central to how the market values the stock over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations